Koglin J
Medizinische Klinik I Universitätsklinikum Grosshadern Marchioninistr. 15 81377 München, Germany.
Z Kardiol. 2000;89 Suppl 9:IX/24-7. doi: 10.1007/s003920070022.
In the cytokine-enriched environment of the chronically rejecting allograft, nitric oxide (NO) is predominantly produced by the inducible isoform of NOS synthase (NOS2) expressed by recipient-derived infiltrating immune cells as well as donor-derived vascular smooth muscle cells and endothelial cells. Early and persistent upregulation of NOS2 in allografts with cardiac allograft vasculopathy and downregulation of NOS2 coinciding with immunosuppressive attenuation of cardiac allograft vasculopathy have suggested NO as a regulator of cardiac allograft vasculopathy, the hallmark of chronic rejection. Pathogenetically, the development of cardiac allograft vasculopathy can be divided into an early phase, characterized by endothelial dysfunction, and a later phase, characterized by structural changes of vessel wall morphology. Several lines of evidence have shown that NO might play an essential role in both phases. Endothelial dysfunction due to immune-mediated injury of endothelial cells has been suggested as an early response-to-injury event in the pathogenesis of cardiac allograft vasculopathy. Functional studies in human transplant recipients have documented endothelial dysfunction of coronary artery vessels. Administration of L-arginine, the precursor of NO, improved endothelial function of both epicardial coronary arteries and coronary microvasculature indicating a protective effect of NO. To assess the impact of NO on the development of late structural changes, the severity of cardiac allograft vasculopathy was assessed in mice with targeted deletion of NOS2. A significant increase of vascular occlusion in NOS2-knockout mice demonstrated an antiarteriosclerotic effect of NOS2. In part, this effect could be explained by reduced neointimal smooth muscle cell accumulation after alloimmune injury. Taken together, NO plays an important role in maintaining vessel integrity after transplantation. Disruptions in NO pathways seem to play a key role in the progression from endothelial dysfunction to structural changes.
在慢性排斥反应的同种异体移植物富含细胞因子的环境中,一氧化氮(NO)主要由受者来源的浸润免疫细胞以及供者来源的血管平滑肌细胞和内皮细胞表达的诱导型一氧化氮合酶(NOS2)产生。心脏同种异体移植血管病变的同种异体移植物中NOS2的早期持续上调以及与心脏同种异体移植血管病变免疫抑制减弱同时出现的NOS2下调表明,NO是慢性排斥反应标志——心脏同种异体移植血管病变的调节因子。从发病机制上讲,心脏同种异体移植血管病变的发展可分为早期阶段,其特征为内皮功能障碍,以及后期阶段,其特征为血管壁形态的结构变化。多项证据表明,NO可能在这两个阶段都发挥着重要作用。内皮细胞免疫介导损伤导致的内皮功能障碍被认为是心脏同种异体移植血管病变发病机制中的早期损伤反应事件。对人类移植受者的功能研究记录了冠状动脉血管的内皮功能障碍。给予NO的前体L-精氨酸可改善心外膜冠状动脉和冠状微血管的内皮功能,表明NO具有保护作用。为了评估NO对后期结构变化发展的影响,在靶向缺失NOS2的小鼠中评估了心脏同种异体移植血管病变的严重程度。NOS2基因敲除小鼠血管闭塞的显著增加证明了NOS2的抗动脉粥样硬化作用。部分这种作用可以通过同种异体免疫损伤后内膜平滑肌细胞积累减少来解释。综上所述,NO在移植后维持血管完整性方面发挥着重要作用。NO途径的破坏似乎在从内皮功能障碍到结构变化的进展中起关键作用。